Bostick-Bruton F - Search Results

1

Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells.

Li Q, Zhang L, Tsang B, Gardner K, Bostick-Bruton F, Reed E. Li Q, et al. Among authors: bostick bruton f. Cell Mol Life Sci. 1999 Mar;55(3):456-66. doi: 10.1007/s000180050302. Cell Mol Life Sci. 1999. PMID: 10228559 Free PMC article.

2

Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line.

Li Q, Bostick-Bruton F, Reed E. Li Q, et al. Anticancer Res. 1998 Jul-Aug;18(4A):2283-7. Anticancer Res. 1998. PMID: 9703867

3

Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.

Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Li Q, et al. J Biol Chem. 1998 Sep 4;273(36):23419-25. doi: 10.1074/jbc.273.36.23419. J Biol Chem. 1998. PMID: 9722577 Free article.

4

Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells.

Li Q, Ding L, Yu JJ, Mu C, Tsang B, Bostick-Bruton F, Reed E. Li Q, et al. Among authors: bostick bruton f. Int J Oncol. 1998 Nov;13(5):987-92. doi: 10.3892/ijo.13.5.987. Int J Oncol. 1998. PMID: 9772291

5

Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells.

Li Q, Tsang B, Bostick-Bruton F, Reed E. Li Q, et al. Among authors: bostick bruton f. Biochem Pharmacol. 1999 Feb 15;57(4):347-53. doi: 10.1016/s0006-2952(98)00291-3. Biochem Pharmacol. 1999. PMID: 9933022

6

Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E. Yu JJ, et al. Among authors: bostick bruton f. Int J Oncol. 2000 Mar;16(3):555-60. doi: 10.3892/ijo.16.3.555. Int J Oncol. 2000. PMID: 10675489

7

Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.

Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E. Li Q, et al. Among authors: bostick bruton f. Anticancer Res. 2000 Mar-Apr;20(2A):645-52. Anticancer Res. 2000. PMID: 10810335

8

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.

Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. Dabholkar M, et al. J Natl Cancer Inst. 1992 Oct 7;84(19):1512-7. doi: 10.1093/jnci/84.19.1512. J Natl Cancer Inst. 1992. PMID: 1433335

9

Peripheral blood leukocytes as a surrogate marker for cisplatin drug resistance: studies of adduct levels and the repair gene ERCC1.

Parker RJ, Poirier MC, Bostick-Bruton F, Vionnet J, Bohr VA, Reed E. Parker RJ, et al. Basic Life Sci. 1990;53:251-61. doi: 10.1007/978-1-4613-0637-5_20. Basic Life Sci. 1990. PMID: 1704215 No abstract available.

10

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Parker RJ, et al. J Clin Invest. 1991 Mar;87(3):772-7. doi: 10.1172/JCI115080. J Clin Invest. 1991. PMID: 1999494 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters